Perroud Herman A, Alasino Carlos M, Rico Maria J, Queralt Francisco, Pezzotto Stella M, Rozados Viviana R, Scharovsky O Graciela
Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
National Scientific & Technological Research Council (CONICET), Rosario, Argentina.
Future Oncol. 2016 May;12(10):1233-42. doi: 10.2217/fon-2016-0075. Epub 2016 Mar 7.
The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib.
MATERIAL & METHODS: Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET).
A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional well-being and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it.
Patients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment.
本研究的目的是检测接受每日低剂量环磷酰胺和塞来昔布节拍化疗的转移性乳腺癌患者的生活质量（QoL）变化。
纳入一项II期试验中接受节拍环磷酰胺和塞来昔布治疗的患者进行生活质量研究。每2个月通过癌症治疗功能评估乳腺（FACT-B）问卷、简明疼痛量表和东部肿瘤协作组量表对生活质量进行评估。在三个时间点分析数据：基线（BL）；治疗中期（MT）；治疗结束（ET）。
共纳入20例患者。所有患者均经过大量前期治疗。治疗显示出良好且安全的治疗效果。使用FACT-B问卷，在反应期（BL-MT）未观察到显著差异。然而，当将最后一个时间点纳入分析（BL-MT-ET）时，在情感幸福和其他问题维度上观察到显著增加。比较BL和ET时，疼痛患者比例显著降低（p = 0.046）。东部肿瘤协作组量表评估显示，26.7%（4/15）的患者功能状态改善，40%（6/15）无变化，而33.3%（5/10）的患者功能状态恶化。
接受数月节拍化疗的患者生活质量未恶化。高比例患者显示改善或无变化，且治疗结束时疼痛患者减少。
